Üriner İnkontinans Medikal Tedavisi

Abstract

Üriner inkontinans istemsiz idrar kaçırma olarak tanımlanır. Her yaş grubundan kadını etkileyebilen bu durum hastanın günlük yaşamında ciddi sıkıntılar meydana getirmektedir. Üriner inkontinans, stres üriner inkontinans, urge üriner inkontinans,miks üriner inkontinans ve aşırı aktif mesane olmak üzere alt gruplara ayrılır. Üriner inkontinans insidansı yaşlabirlikte artar ve stres üriner inkontinans genç kadınlarda daha sık görülür. Bu çalışma bu konuda son uluslararası literatür verileri karşılaştırılarak yapılmıştır. Bu yazının amacı üriner inkontinans medikal tedavisi hakkında genel bir bakış vermektir.

Üriner İnkontinans Medikal Tedavisi

Abstract

Urinary incontinence is defi ned as involuntary leakage of urine. This situation may effect all age groups women and constitute serious problems that may affect the patient's daily life. Urinary incontinence is divided into sub-groups, including stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence and overactive bladder. The incidence of urinary incontinence increases with age and while stress urinary incontinence is more common in younger women. The study was conducted by comparing the data of the recent international literature on this topic. The purpose of this paper is to give an overview on the pharmacotherapy of urinary incontinence 

Keywords

• xx

References

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of
2. lower urinary tract function. Report from the standardisation committee of
3. the International Continence Society. Neurourol Urodynam 2002;21:167–
4. -
5. Rortveit G, Hunskaar S. Urinary incontinence and age at the first and last
6. delivery: the Norwegian HUNT/EPINCONT study. Am J Obstet Gynecol
7. ;195(2):433Y438.
8. Urinary incontinence in women: the management of urinary incontinence in

9. women. National Collaborating Centre for Women’s and Children’s Health.
10. Royal College of Obstetricians and Gynaecologists, September 2013.
11. Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary
12. incontinence. Eur Urol 2011;59(3):387-400.
13. McGrother CW, Donaldson MM, Hayward T, et al. Urinary storage
14. symptoms and comorbidities: a prospective population cohort study in
15. middle-aged and older women. Age and Ageing 2006;35(1):16–24.
16. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide
17. problem. International Journal of Gynaecology and Obstetrics
18. ;82(3):327–38.
19. Shamliyan T,Wyman JF, Ramakrishnan R, et al. Benefits and harms of
20. pharmacologic treatment for urinary incontinence in women: a systematic
21. review. Ann Intern Med 2012;156(12):861-874.
22. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic
23. treatments in overactive bladder: an update of a systematic review and
24. meta-analysis. Eur Urol 2008;54:543Y562.
25. Cipullo LM, Zullo F, Cosimato C, Di Spiezio Sardo A, Troisi J, Guida M.
26. Pharmacological treatment of urinary incontinence.Female Pelvic Med
27. Reconstr Surg. 2014 Jul-Aug;20(4):185-202.
28. Cipullo LM, Cosimato C, Filippelli A, Conti V, Izzo V, Zullo F, Guida
29. M.Pharmacological approach to overactive bladder and urge urinary
30. incontinence in women: an overview.Eur J Obstet Gynecol Reprod Biol.
31. Mar;174:27-34.
32. Cardozo L, Hebdorfer E, Milani R, et al. Solifenacin in the treatment of
33. urgency and other symptoms of overactive bladder; results from a
34. randomised, doubleblind, placebo-controlled, rising dose trial. BJU Int
35. ;102:1120–7.
36. Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group.
37. Long-term open label solifenacin treatment associated with persistence
38. with therapy in patients with overactive bladder syndrome. Eur Urol
39. ;47:376–84.
40. Cardozo L, Dixon A. Increased warning time with Darifenacin: a new
41. concept in the management of urinary urgency. J Urol 2005;173:1214–8.
42. Siddighi S, Chuan S. Medicine used in urogynecology. In: Siddighi S,
43. Hardesty JS, eds. Urogynecology and Female Pelvic Reconstructive Surgery:
44. Just the Facts. New York, NY: McGraw-Hill-Medical Publishing Division;
45. -
46. Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, Sparf B. Tolterodine—a
47. new bladder selective antimuscarinic agent. Eur J Pharmacol 1997;327:195–
48. -
49. Nilvebrant L, Halle´n B, Larsson G, et al. TolterodineVa new bladder selective
50. muscarinic receptor antagonist: preclinical pharmacological and clinical
51. data. Life Sci 1997;60(13-14):1129-1136.
52. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for
53. overactive bladder symptoms in adults. Cochrane Database Syst Rev
54. ;1:CD005429.
55. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of
56. overactive bladder: a poled analysis. Urology 1997;50:90–6.
57. Swift S, Garely A, Dimpfl T, Payne C, Tolterodine Study Group. A new
58. once daily formulation of tolterodine provides superior efficacy an is well
59. tolerated in women with overactive bladder. Int J Pelvic Floor Dysfunct
60. ;14(1):50–4.
61. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomised, double blind
62. study of the efficacy and tolerability of the extended-release formulations
63. of oxybutynin and tolterodine for overactive bladder: results of the OPERA
64. trial. Mayo Clin Proc 2003;78(6):687–95.
65. Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz
66. G. Trospium chloride versus oxybutynin: a randomized, double-blind,
67. multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol
68. ;75:452– 6.
69. Osca JM, Martinez-Agullo E, Broseta E, et al. Trospium chloride versus
70. oxybutynin in the treatment of bladder neurological disorders: a double
71. blind randomized clinical trial [Abstract]. Br J Urol 1997;80(Suppl 2):12.
72. Alabaster VA. Discovery and development of selective M3 antagonists for
73. clinical use. Life Sci 1997;60(13-14):1053-1060
74. Haab F, Stewart L, Dwyer P. Darifenacin an M3 selective receptor
75. antagonist, is an effective and well-tolerated once-daily treatment for
76. overactive bladder. Eur Urol 2004 Apr;45(4):420–9.
77. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis
78. of randomized controlled trials with antimuscarinic drugs for overactive
79. bladder. Eur Urol 2008;54:740–64.
80. Chapple CR. Darifenacin is well tolerated and provides significant
81. improvement in the symptoms of overactive bladder: a pooled analysis of
82. phase III studies. J Urol 2004;171(Suppl):130 [abstract 487].
83. Ginsberg D, Schneider T, Kelleher C, et al. Efficacy of fesoterodine
84. compared with extended-release tolterodine in men and women with
85. overactive bladder. BJU Int 2013;112:373–85.
86. Chapple CR, Van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M.
87. Comparison of Fesoterodine and tolterodine in patients with overactive
88. bladder. BJU Int 2008;102:1128–32.
89. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for
90. overactive bladder symptoms in adults. Cochrane Database Syst Rev
91. ;1:CD005429.5-31
92. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. ICS guidelines 2009.In: 4th international consultation
93. on incontinence. Curr Opin Urol 2009;19:380–94.
94. Siddighi S, Hardesty JS, editors. Urogynecology and female pelvic
95. reconstructive surgery: just the facts. New York: McGraw-Hill – Medical
96. Publishing Division; 2006
97. Jumadilova Z, Varadharajan S, Girase P, Ollendorf DA. Retrospectiveevaluation of outcomes in patients with overactive bladder receiving
98. tolterodine versus oxybutynin. Am J Health Syst Pharm 2006;63:2357–64.
99. Robinson D, Cardozo L. New drug treatments for urinary incontinence.
100. Maturitas 2010;65:340–7.
101. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety
102. of transdermal oxybutynin and oral tolterodine versus placebo in previously
103. treated patients with urge and mixed urinary incontinence. Urology
104. ;62(2):237–42.
105. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin
106. chloride topical gel for overactive bladder: a randomised, double blind,
107. placebo controlled, multicentre study. J Urol 2009;181:1764–72.
108. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder
109. AM. Solifenacin appears effective and well tolerated in patients with
110. symptomatic idiopathic detrusor overactivity in a placebo and tolterodine
111. controlled phase II dosefinding study. BJU Int 2004;93:71–7.
112. Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind
113. placebo-controlled multicentre study to explore the efficacy and safety of
114. tamsulosin and tolterodine in women with overactive bladder syndrome.
115. BJU Int 2007;100(4):840Y845.
116. Sanford M. Mirabegron: a review of its use in patients with overactive
117. bladder syndrome. Drugs 2013;73:1213–25.
118. Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin
119. Drug Saf 2011;10:287–94.
120. Caremel R, Loutochin O, Corcos J. What do we know and not know about
121. mirabegron, a novel b3 agonist, in the treatment of overactive bladder? Int
122. Urogynecol J. 2014 Feb;25(2):165-70.
123. Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III
124. trial of mirabegron in patients with overactive bladder. J Urol 2012;S0022-
125. (12): 05216-05210
126. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind,
127. active-controlled phase 3 study to assess 12-month safety and efficacy of
128. mirabegron, a A(3)-adrenoceptor agonist, in overactive bladder. Eur Urol
129. ;63(2):296-305.
130. U.S. Food and Drug Administration. FDA News Release [FDA web site].
131. August 25, 2011. Available at: http://www.fda.gov/ News Events/
132. Newsroom/ Press Announcements/ ucm 269509 .htm. Accessed August
133. , 2012.
134. Allergan. Long term follow-up study of safety and efficacy of botulinum
135. toxin type A for the treatment of patients with idiopathic overactive bladder
136. with urinary incontinence. Last update January 17, 2012.
137. de Groat WC. A neurologic basis for the overactive bladder. Urology
138. ;50(6A Suppl):36Y52; discussion 53.
139. Chai TC, Gray ML, Steers WD. The incidence of a positive ice water test in
140. bladder outlet obstructed patients: evidence for bladder neural plasticity. J
141. Urol 1998;160(1):34. 3-7.
142. Lazzeri M, Spinelli M, Beneforti P, et al. Intravesical resiniferatoxin for the
143. treatment of detrusor hyperreflexia refractory to capsaicin in patients with
144. chronic spinal cord diseases. Scand J Urol Nephrol 1998;32(5):331.
145. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in
146. patients with idiopathic detrusor instability suggests that involuntary
147. detrusor contractions are triggered by C-fiber input. J Urol 2002;168(2):575.
148. Thor KB, Katofiasc MA. Effects of Duloxetine, a combined serotonin and
149. norepineephrine reuptake inhibitor, on central neural control of lower
150. urinary tract function in the chloralose-anesthetised female cat. J Pharmacol
151. Exp Ther 1995;274:1014–24.
152. Norton PA, Zinner NR, Yalcin I, Bump RC, Duloxetine Urinary Incontinence
153. Study Group. Duloxetine versus placebo in the treatment of stress urinary
154. incontinence. Am J Obstet Gynaecol 2002;187(1):40–8.
155. Millard R, Moore K, Yalcin I, Bump R. Duloxetine vs. placebo in the
156. treatment of stress urinary incontinence: a global phase III study. Neurourol
157. Urodynam 2003;22:482–3.
158. Baldessarini KJ. Drugs in the treatment of psychhiatric disorders. In: Gilman,
159. et al., editors. The pharmacological basis of theraputics. 7th ed. McMillan
160. Publishing Co.; 1985. p. 387–445.
161. Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine
162. and placebo for incontinence due to bladder instability. Age Aging
163. ;15:299–303.
164. Saks EK, Arya LA. Pharmacologic management of urinary incontinence,
165. voiding dysfunction, and overactive bladder. Obstet Gynecol Clin North Am
166. ;36(3):493-507.
167. Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary
168. incontinence in post-menopausal women. Cochrane Database Syst Rev
169. ;10:CD001405